Details

MIPS - Quality Measures - Psoriasis: Clinical Response to Oral Systemic or Biologic Medications

Quality Measures
Category QUALITY
Description Percentage of psoriasis patients receiving oral systemic or biologic therapy who meet minimal physician-or patient- reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment
eMeasure ID
First Performance Year 2017
Last Performance Year
Metric Type Single Performance Rate
National Quality Strategy Domain PCCEO
Measure Type Outcome
eMeasure UUID
NQF eMeasure ID
NQF ID
Is High Priority?
Is Inverse?
Overall Algorithm
Primary Steward American Academy of Dermatology
Submission Methods Claims | Registry
Eligibility Options
Performance Options
Is Risk Adjusted?
Vendor ID
Is Registry Measure?
Registry Measure Spec https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_410_Registry.pdf
Web Interface Measure Spec
Claims Measure Spec https://qpp.cms.gov/docs/QPP_quality_measure_specifications/Claims-Registry-Measures/2017_Measure_410_Claims.pdf

Back to List